Secretoneurin and the tachykinins substance P and neurokinin-A/B in NMDA-induced excitotoxicity in the rat retina

Teuchner, Barbara; Dimmer, Andreas; Troger, Josef; Fischer‐Colbrie, Reiner; Schmid, E. D.; Kieselbach, G.; Dietrich, Hermann; Bechrakis, Nikolaos E.

doi:10.1016/j.regpep.2010.01.007

Cited by 6 publications

(5 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, P2 and N2 (at Cz point of recording) showed significant statistical delay in patients than controls in both eyes. The present results agreed with McDonald et al, 2007and dos Santo and Alencer 2010 who reported that malnourished children had a significant delay in VEPs and are less sensitive to the frequencies of the waves than the normal healthy children [36,37] . Furthermore, the present findings showed that there were insignificant decrease in O2, O1 and Cz amplitudes between both control and patient groups.…”

Section: Discussionsupporting

confidence: 93%

“…Also, N2 and P2 of Oz latencies in the moderate and severe malnutrition children were delayed significantly (p<0.05) than the normal children. These results are in line with McDonald et al, 2007;Durmaz et al, 1999and Faldella et al, 1996 who found that children with PEM had obvious delay in visual evoked potentials [36], [39][40] . Significant reduction in nerve conduction velocity may be due to nutritional deficiency affecting myelination of peripheral nerves.…”

Section: Discussionsupporting

confidence: 86%

“…This was in disagreement with McDonald et al, 2007 who performed fVEPs which continued to show abnormality at discharge. They suggested the possibility that nutritional rehabilitation did not fully eliminate the physiological deficit [36] …”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Estimation of Serum Neurokinin A Level in Correlation to Visual Evoked Potentials and Morphological Brain Changes in Malnourished Children: A Follow-Up Case-Control Study

Hassan¹

2016

jmscr

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 93%

Section: Discussionsupporting

confidence: 86%

See 1 more Smart Citation

Estimation of Serum Neurokinin A Level in Correlation to Visual Evoked Potentials and Morphological Brain Changes in Malnourished Children: A Follow-Up Case-Control Study

Hassan¹

2016

jmscr

View full text Add to dashboard Cite

“…Based on my PubMed search, an impressive number of papers (more than 20 000) have been published in the last 10 years on the diagnosis, pathomechanism and treatment of the above‐mentioned conditions. However, very few of these papers have dealt with the possible role of neuropeptides in the pathomechanisms of human retinal degenerations; at the same time, a number of articles have provided evidence for structural and functional protection mediated by neuropeptides during conditions of metabolic stress in experimental models .…”

Section: Introductionmentioning

confidence: 99%

Neuropeptides and diabetic retinopathy

Gábriel¹

2013

Brit J Clinical Pharma

View full text Add to dashboard Cite

Diabetic retinopathy, a common complication of diabetes, develops in 75% of patients with type 1 and 50% of patients with type 2 diabetes, progressing to legal blindness in about 5%. In the recent years, considerable efforts have been put into finding treatments for this condition. It has been discovered that peptidergic mechanisms (neuropeptides and their analogues, activating a diverse array of signal transduction pathways through their multiple receptors) are potentially important for consideration in drug development strategies. A considerable amount of knowledge has been accumulated over the last three decades on human retinal neuropeptides and those elements in the pathomechanisms of diabetic retinopathy which might be related to peptidergic signal transduction. Here, human retinal neuropeptides and their receptors are reviewed, along with the theories relevant to the pathogenesis of diabetic retinopathy both in humans and in experimental models. By collating this information, the curative potential of certain neupeptides and their analogues/antagonists can also be discussed, along with the existing clinical treatments of diabetic retinopathy. The most promising peptidergic pathways for which treatment strategies may be developed at present are stimulation of the somatostatin-related pathway and the pituitary adenylyl cyclase-activating polypeptide-related pathway or inhibition of angiotensinergic mechanisms. These approaches may result in the inhibition of vascular endothelial growth factor production and neuronal apoptosis; therefore, both the optical quality of the image and the processing capability of the neural circuit in the retina may be saved.

show abstract

“…In addition, results from studies in diabetic rats showed that the levels of SP in the retina and serum were reduced, with an associated increase in apoptosis and caspase-3 activity, while the restoration of endogenous SP levels paralleled the inhibition of apoptosis [146]. Similarly, the levels of SP and NKA/NKB decreased in an NMDA–excitotoxicity model of the rat retina [147], while both the severe retinal destruction and the dense neovascularization in laser-induced retinal degeneration models recovered after SP administrations [148]. Noteworthy, SP treatment suppressed early inflammatory responses in proliferative vitreoretinopathy-like retinal damage, with inhibition of cell death, limitation of the appearance of fibroblastic cells, and delay of the progression of retinal degeneration [149].…”

Section: Substance Pmentioning

confidence: 99%

Neuroprotective Peptides in Retinal Disease

Cervia

Catalani

Casini

2019

JCM

View full text Add to dashboard Cite

In the pathogenesis of many disorders, neuronal death plays a key role. It is now assumed that neurodegeneration is caused by multiple and somewhat converging/overlapping death mechanisms, and that neurons are sensitive to unique death styles. In this respect, major advances in the knowledge of different types, mechanisms, and roles of neurodegeneration are crucial to restore the neuronal functions involved in neuroprotection. Several novel concepts have emerged recently, suggesting that the modulation of the neuropeptide system may provide an entirely new set of pharmacological approaches. Neuropeptides and their receptors are expressed widely in mammalian retinas, where they exert neuromodulatory functions including the processing of visual information. In multiple models of retinal diseases, different peptidergic substances play neuroprotective actions. Herein, we describe the novel advances on the protective roles of neuropeptides in the retina. In particular, we focus on the mechanisms by which peptides affect neuronal death/survival and the vascular lesions commonly associated with retinal neurodegenerative pathologies. The goal is to highlight the therapeutic potential of neuropeptide systems as neuroprotectants in retinal diseases.

show abstract

Secretoneurin and the tachykinins substance P and neurokinin-A/B in NMDA-induced excitotoxicity in the rat retina

Cited by 6 publications

References 39 publications

Estimation of Serum Neurokinin A Level in Correlation to Visual Evoked Potentials and Morphological Brain Changes in Malnourished Children: A Follow-Up Case-Control Study

Estimation of Serum Neurokinin A Level in Correlation to Visual Evoked Potentials and Morphological Brain Changes in Malnourished Children: A Follow-Up Case-Control Study

Neuropeptides and diabetic retinopathy

Neuroprotective Peptides in Retinal Disease

Contact Info

Product

Resources

About